What does the KESETT study show about adding ketamine to levetiracetam for benzodiazepine‑refractory status epilepticus in patients ≥1 year old weighing ≥10 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

KESETT Study Overview

The KESETT study is a proposed three-armed, Bayesian adaptive randomized trial comparing two doses of ketamine plus levetiracetam versus levetiracetam alone for benzodiazepine-refractory status epilepticus in patients ≥1 year old weighing ≥10 kg 1.

Study Design and Methodology

The KESETT trial employs a novel statistical approach using an ordinal primary outcome at 60 minutes with five levels ranging from:

  • Level 1: Improving consciousness and seizure cessation (best outcome)
  • Level 5: Life-threatening event or death (worst outcome)

The study specifically addresses a methodological challenge: the expected bimodal distribution of outcomes in status epilepticus, where patients tend to cluster at either end of the outcome spectrum (either doing well or very poorly). This distribution violates the proportional odds assumption used in traditional ordinal analyses 1.

Key Methodological Innovation

The investigators developed an expected score approach derived from posterior distributions for each treatment group. This method:

  • Requires minimal statistical assumptions
  • Maintains the benefit of using the full ordinal scale
  • Provides interpretable results within a Bayesian framework
  • Controls type I error and power effectively
  • Results in a sizable reduction in sample size compared to non-parametric tests 1

Clinical Context and Rationale

Why This Study Matters

Current guidelines establish that levetiracetam, fosphenytoin, and valproate are equally effective as second-line agents for benzodiazepine-refractory status epilepticus, with seizure cessation rates of approximately 45-47% at 60 minutes 2. This leaves roughly half of patients requiring additional therapy.

Ketamine is increasingly recognized as a promising agent for refractory and super-refractory status epilepticus:

  • Recent meta-analysis shows 64% pooled seizure cessation rate (95% CI 49%-76%) when ketamine is used in refractory cases 3
  • Earlier initiation appears beneficial: responders received ketamine at 3.2 days versus 4.3 days for non-responders (mean difference -0.90 days, p<0.0001) 3
  • Adverse events requiring discontinuation are rare (0.7%) 3

The Treatment Gap

Guidelines acknowledge the need for additional research on ketamine for status epilepticus 2. The 2025 guidance mentions ketamine as an intervention "occasionally used in tertiary centres" for continuing status epilepticus 4, but lacks specific dosing recommendations or evidence-based protocols for its use as an early adjunctive therapy.

KESETT's Unique Contribution

KESETT is the first prospective randomized trial testing ketamine as an adjunct to levetiracetam in the established (benzodiazepine-refractory) phase, rather than waiting for refractory or super-refractory status epilepticus. This represents a paradigm shift toward earlier, more aggressive combination therapy.

The study tests two ketamine doses plus levetiracetam, allowing dose-response evaluation while maintaining levetiracetam as the backbone therapy consistent with current guidelines 2.

Supporting Pharmacokinetic Work

Parallel research has developed machine learning models to predict early ketamine exposure (AUC0-2h) using only two samples per patient, addressing the practical challenge of intensive pharmacokinetic sampling in pediatric emergency settings 5. This work supports feasibility of the KESETT trial in the target population.

Clinical Implications If Positive

If KESETT demonstrates superiority of ketamine plus levetiracetam over levetiracetam alone, it would:

  • Provide the first Level 1 evidence for early ketamine use in status epilepticus
  • Potentially increase the 47% success rate seen with levetiracetam monotherapy 2
  • Reduce progression to refractory status epilepticus, thereby reducing morbidity and mortality
  • Establish evidence-based dosing for ketamine in this indication
  • Support earlier, more aggressive treatment before patients deteriorate to super-refractory status

Current Evidence Limitations

Existing ketamine data comes primarily from:

  • Retrospective case series
  • Patients with already-refractory or super-refractory status epilepticus
  • Heterogeneous treatment protocols and timing 3

KESETT addresses these limitations through prospective randomization, standardized timing (immediately after benzodiazepine failure), and rigorous outcome assessment.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.